US Patent 7919090 Antibody therapy
Patent 7919090 was granted and assigned to IMMUNOMEDICS, INC. on April, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+284 characters)
Article
Patent abstract
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07919090 Antibody therapy US Patent 7919090 Antibody therapy
Infobox
Patent Number
0791909000
Patent Number
791909000
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079190900
Date of Patent
April 5, 2011
0Patent Application Number
126392980
Date Filed
December 16, 2009
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079190900
Date of Patent
April 5, 2011
0Patent Application Number
126392980
Date Filed
December 16, 2009
0Official Website
Patent Primary Examiner
Edits on 19 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07919090 Antibody therapy
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07919090
Date of patent
April 5, 2011
Patent application number
12639298
Date Filed
December 16, 2009
Patent primary examiner
Find more entities like US Patent 7919090 Antibody therapy
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
